All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ASCO 2016 | Higher Rate of ORR Achieved with Mogamulizumab vs Investigator’s Choice for Treatment of R/R ATL

By Terri Penfold

Share:

Nov 15, 2016


This ASCO 2016 oral abstract presentation took place on Sunday June 5, 9:45am–12:45pm, during the ‘Hematologic Malignancies-Lymphoma and Chronic Lymphocytic Leukemia’ session. This session was chaired by Pr Gilles Salles, Head of the Hematology Department in South Lyon hospitals, Lyon, France.

This abstract (#7501) was presented by Adrienne Alise Phillips, Assistant Professor of Clinical Medicine, New York-Presbyterian/Columbia University Medical Center in New York.

Adult T-cell Leukemia-Lymphoma (ATL) is a malignancy which arises from HTLV-1 infected T-cells. It carries a poor prognosis is poor and subtype related. Currently, there is no agreement on standard treatment for R/R patients with aggressive disease; whose median OS is less than 3 months.

Mogamulizumab (moga) is an anti-CCR4 monoclonal antibody; CCR4 is expressed in nearly all (>90%) of ATL cases. Moga holds Japanese approval for the treatment of CCR4+ ATL, PTCL, and CTCL.

The efficacy of moga was assessed outside of Japan in a multicenter, open-label, randomized study (NCT01626664), which enrolled patients with aggressive R/R ATL (acute, lymphomatous, and chronic subtypes) from sites in the USA, EU, and Latin America. ATL treatment with moga was compared to treatment with Investigator’s Choice (IC) treatment.

Beginning in June 2012, the primary outcome of this study was ORR, supplemented by secondary outcome measures such as PFS, OS, and QoL. Inclusion criteria included, but was not limited to, ≥18 years of age, confirmed ATL diagnosis (excluding smoldering type), and ECOG performance score of  ≤2.

Overall, 71 patients were randomized 2:1 to receive either moga 1.0mg/kg given weekly for the first 4-week cycle and then biweekly (n=47), or to 1 of 3 IC regimens (Gem/Ox, DHAP, or pralatrexate; n=24). Due to ATL being so rare, and lack of effective therapy, no power calculation was performed. Patients receiving IC therapy arm could cross-over to moga if they experienced disease progression.

  • With moga, ORR by Independent Review (IR) = 23.4% (11/47); ORR by Investigator (IA) = 34.0% (16/47)
  • With IC, ORR by IR = 8.3% (2/24); ORR by IA = 0%
  • With moga, confirmed ORR (maintained response after 1 month) by IR = 10.6%; by IA = 14.9% by IA
  • No confirmed responses found for the IC group
  • Of the 18 IC pts who crossed over to moga, 3 (17%) responded
  • With moga, median DoR by IA = 5.5 months; by IR = 5.0 months (range, 3.8–9.6 months); 1 patient had CR lasting >9 months
  • The most common treatment-emergent, drug-related AEs with moga were infusion reactions (46.8%), rash/drug eruption (25.5%), and infections (14.9%)

So far, this was the largest randomized clinical trial of R/R ATL. In patients with aggressive R/R ATL commonly used cytotoxic regimens resulted in little to no responses, whereas treatment with moga resulted in an ORR that supports its therapeutic potential in this setting.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?